News

Immuneed secures SEK 9M

Immuneed has secured SEK 9M in an oversubscribed financing round. The funding will support the pre-clinical work of our Immuno-Oncology cancer vaccine and be used to increase marketing of the companys analysis service. The new funding secures financing of our pre-clinical program for the cancer vaccine and further engagement for contract manufacturing.

Quick Links

Dag Hammarskjölds väg 13a | 752 37 Uppsala, Sweden | info@immuneed.com